Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arexvy immune persistence and revaccination extension in kidney and lung transplant recipients
2024-519730-23-00Phase 2Authorised
- Sponsor
- GSK
- Start
- Nov 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 2, open-label trial of GSK3003899A in respiratory syncytial virus disease (RSV) (2 cohorts), sponsored by GSK. Planned start Nov 2025; status: authorised.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2024-519730-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519730-23-00.